EX-99.1 2 tm2012017d3_ex99-1.htm EXHIBIT 99.1


Exhibit 99.1




Menlo Reports Financial Results for Subsidiary Foamix Pharmaceuticals for Year Ended December 31, 2019


Foamix Became a Wholly Owned Subsidiary of Menlo Therapeutics Upon Closing of Merger on March 9, 2020


Menlo Conference Call and Webcast Scheduled for Thursday, March 12th at 8:30am Eastern Time


BRIDGEWATER, N.J., March 12, 2020 -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced financial results for its wholly-owned subsidiary, Foamix Pharmaceuticals Ltd. (“Foamix”), for the twelve months ended December 31, 2019 and provided a corporate update. Menlo and Foamix announced the consummation of their merger transaction on March 9, 2020.  


Recent pipeline highlights:

·The U.S. Food and Drug Administration (FDA) approved AMZEEQ™ (minocycline) topical foam, 4%, for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in adults and pediatric patients nine years of age and older. AMZEEQ™ is the first topical formulation of minocycline to be approved by the FDA for any condition. Foamix commercially launched AMZEEQ™ in the U.S. in January 2020.
·A New Drug Application (NDA) was submitted to the FDA for FMX103 (minocycline) topical foam, 1.5%, for the treatment of papulopustular rosacea in adults. The FDA set a Prescription Drug User Fee Act (PDUFA) action date of June 2, 2020. If approved, FMX103 would be the first minocycline product available for rosacea patients.
·Enrollment has been completed in the ongoing Phase 2 trial for FCD105, a topical combination foam of minocycline and adapalene, currently being evaluated for the treatment of moderate-to-severe acne vulgaris. Topline data from this trial are expected in the second quarter of 2020.
·Serlopitant is being evaluated in two Phase 3 clinical trials for the treatment of pruritus associated with prurigo nodularis (PN). The studies are fully enrolled, with results expected in March or April 2020. Assuming successful completion of the Phase 3 clinical trials, an NDA submission for serlopitant for the treatment of pruritus in PN is planned in the second half of 2020.


Financial Results for Foamix Pharmaceuticals for the Year Ended December 31, 2019


The following financial results pertain only to Menlo's wholly-owned subsidiary, Foamix Pharmaceuticals Ltd. Foamix Pharmaceuticals is filing its last Form 10-K this week, and Menlo does not intend to provide separate financial results for Foamix Pharmaceuticals in the future.




Total revenues, consisting primarily of royalties, decreased by $3.2 million, or 89%, from $3.6 million in the year ended December 31, 2018 to $0.4 million in the year ended December 31, 2019, due to the ongoing suspension of the manufacturing and sales of Finacea by LEO, following inadequate supply of quality-compliant batches of the API used in such product.





Research and Development Expenses


Research and development expenses for the year ended December 31, 2019 were $51.2 million, representing a decrease of $13.3 million, or 21%, compared to $64.5 million for the year ended December 31, 2018. The decrease in research and development expenses resulted primarily from decrease of $21.4 million in clinical trial expenses due to the completion of AMZEEQ and FMX103 clinical trials, offset by an increase of $3.2 million in consulting expenses, an increase of $2.8 million in payroll and payroll-related expenses due to an increase in headcount and salaries and an increase of $2.6 million in payments related to the submission of our NDA for FMX103.


Selling, General and Administrative Expenses


General and administrative expenses for the year ended December 31, 2019 were $45.1 million, representing an increase of $31.1 million, or 221%, compared to $14.0 million for the year ended December 31, 2018. The increase in selling, general and administrative expenses resulted primarily from an increase of $18.0 million in connection with the pre-commercialization activities, an increase of $5.4 million in payroll and payroll-related expenses due to an increase in headcount as we built out our sales and marketing organization in preparation for the AMZEEQ launch, a $3.1 million increase in costs relating to the merger transaction with Menlo and a $2.0 million increase in other advisor and consulting expenses.


Net Loss


Net loss for the year ended December 31, 2019 was $95.2 million, compared to $74.2 million for the year ended December 31, 2018, an increase of $21.0 million, or 28%.


Cash & Cash Equivalents


At December 31, 2019, Foamix had cash and cash equivalents of $73.4 million, compared to cash and cash equivalents of $99.4 million at December 31, 2018.


Pro Forma Cash Position for Combined Company


At December 31, 2019, the combined pro forma cash position for Menlo, assuming the merger transaction with Foamix Pharmaceuticals was completed on December 31, 2019, was approximately $150.5 million.


Conference Call & Webcast


There will be a conference call at 8:30 a.m. Eastern Time on Thursday, March 12th during which management of Menlo will provide a corporate update.


Thursday, March 12th @ 8:30amET


Toll Free: 877-407-0784
International: 201-689-8560
Conference ID: 13700089
Webcast: http://public.viavid.com/index.php?id=138439


A replay of the call will be archived on the Company’s website at www.menlotherapeutics.com promptly after the conference call.





About Menlo


Menlo Therapeutics Inc. recently combined with Foamix Pharmaceuticals Ltd. to form a different type of biopharmaceutical company working to solve some of today’s most difficult therapeutic challenges in dermatology and beyond.


With expertise in topical medicine innovation as a springboard, the Company is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST™), and has received FDA approval for the world’s first topical minocycline, AMZEEQ™ (minocycline) topical foam, 4%. In addition, the Company is focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, as a novel potential treatment option for pruritus associated with prurigo nodularis.


For more information about Menlo or its investigational products, visit www.menlotherapeutics.com. Menlo may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Menlo’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.


Cautionary Statement Regarding Forward-Looking Statements


This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding expectations with respect to the anticipated announcement of results of Menlo’s clinical trials for pruritus associated with prurigo nodularis, statements regarding the development and commercialization of Menlo’s products and product candidates and other statements regarding the future expectations, plans and prospects of Menlo. All statements in this press release which are not historical facts are forward-looking statements. Any forward-looking statements are based on Menlo’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially and adversely from those set forth or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, Menlo’s ability to successfully integrate the two companies; the achievement of certain expected cost synergies; the outcome of any legal proceedings related to the merger; the outcome and cost of clinical trials for current and future product candidates, including those for serlopitant; determination by the FDA that results from Menlo’s clinical trials are not sufficient to support registration or marketing approval of product candidates; adverse events associated with the commercialization of AMZEEQ™; the outcome of pricing, coverage and reimbursement negotiations with third party payors for AMZEEQ™ or any other products or product candidates that Menlo may commercialize in the future; whether, and to what extent, third party payors impose additional requirements before approving AMZEEQ™ prescription reimbursement; the eligible patient base and commercial potential of AMZEEQ™ or any of Menlo’s other product or product candidates; risks that Menlo’s intellectual property rights, such as patents, may fail to provide adequate protection, may be challenged and one or more claims may be revoked or interpreted narrowly or will not be infringed; risks that any of Menlo’s patents may be held to be narrowed, invalid or unenforceable or one or more of Menlo’s patent applications may not be granted and potential competitors may also seek to design around Menlo’s granted patents or patent applications; additional competition in the acne and dermatology markets; inability to raise additional capital on favorable terms or at all; Menlo’s ability to recruit and retain key employees; and Menlo’s ability to stay in compliance with applicable laws, rules and regulations. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Menlo’s actual results to differ from those contained in the forward-looking statements, see the sections titled “Risk Factors” in (i) Menlo’s most recent annual report on Form 10-K, (ii) Foamix’s most recent annual report on Form 10-K and (iii) Menlo’s definitive joint proxy statement/prospectus filed with the U.S. Securities and Exchange Commission under Rule 424(b)(3) on January 7, 2020, as well as discussions of potential risks, uncertainties, and other important factors in Menlo’s subsequent filings with the U.S. Securities and Exchange Commission. Although Menlo believes these forward-looking statements are reasonable, they speak only as of the date of this announcement and Menlo undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. Given these risks and uncertainties, you should not rely upon forward-looking statements as predictions of future events.





Media Relations:


Vusi Moyo

Zeno Group




Investor Relations:


Joyce Allaire

LifeSci Advisors, LLC











(U.S. dollars in thousands)


   December 31 
   2019   2018 
Cash and cash equivalents  $43,759   $27,868 
Restricted cash   825    250 
Short term bank deposits   12,102    24,047 
Investment in marketable securities   16,246    46,669 
Restricted investment in marketable securities    434    268 
Trade receivable   135    1,066 
Other   1,557    999 
Inventory   1,356    - 
TOTAL CURRENT ASSETS   76,414    101,167 
Investment in marketable securities   -    150 
Restricted investment in marketable securities   -    133 
Property and equipment, net   2,885    2,235 
Operating lease right of use assets   1,694    - 
Other   166    46 
TOTAL  NON-CURRENT ASSETS   4,745    2,564 
TOTAL  ASSETS  $81,159   $103,731 





   December 31 
   2019   2018 
Liabilities and shareholders’ equity           
Trade payables  $19,352   $6,327 
Accrued expenses   3,381    351 
Employee related obligations   5,231    3,498 
Operating lease liabilities   1,092    - 
Other   270    292 
Liability for employee severance benefits   424    367 
Operating lease liabilities   653    - 
Long-term debt   32,725    - 
Other liabilities   456    714 
TOTAL LIABILITIES   63,584    11,549 
Ordinary Shares, NIS 0.16 par value - authorized: 135,000,000 and 90,000,000 Ordinary Shares as of December 31, 2019 and December 31, 2018; issued and outstanding: 61,580,544 and 54,351,140 Ordinary Shares as of December 31, 2019 and December 31, 2018, respectively   2,659    2,331 
Additional paid-in capital   325,498    305,303 
Accumulated deficit   (310,587)   (215,409)
Accumulated other comprehensive income (loss)   5    (43)
TOTAL SHAREHOLDERS' EQUITY   17,575    92,182 









(U.S. dollars in thousands, except per share data)


   Year ended December 31 
   2019   2018   2017 
REVENUES   $443   $3,595   $3,669 
COST OF REVENUES   -    -    13 
GROSS PROFIT   443    3,595    3,656 
OPERATING EXPENSES:               
Research and development   51,202    64,474    57,779 
Selling, general and administrative   45,114    14,013    11,491 
TOTAL OPERATING EXPENSES   96,316    78,487    69,270 
OPERATING LOSS   95,873    74,892    65,614 
FINANCE INCOME   (1,672)   (985)   (1,134)
FINANCE EXPENSES   1,153    44    71 
LOSS BEFORE INCOME TAX   95,354    73,951    64,551 
INCOME TAX   (176)   212    1,164 
NET LOSS FOR THE YEAR  $95,178   $74,163   $65,715 
LOSS PER SHARE BASIC AND DILUTED  $1.66   $1.70   $1.76